Genprex, Inc. - GNPX STOCK NEWS

Genprex, Inc. (Nasdaq: GNPX) has entered into a securities purchase agreement with a healthcare-dedicated institutional investor to sell 3,116,884 shares of its common stock at $3.85 per share. This registered direct offering is priced at-the-market under Nasdaq rules, with no warrants issued. The closing is expected around December 24, 2020, subject to customary conditions. A.G.P./Alliance Global Partners acts as the sole placement agent. The offering is made under an effective shelf registration statement previously filed with the SEC.

Genprex, Inc. (GNPX) has completed the manufacturing scale-up of REQORSA™ immunogene therapy, aimed at supplying the Acclaim-1 and Acclaim-2 clinical trials for non-small cell lung cancer. This production adheres to current Good Manufacturing Practices (cGMP) and includes significant advancements that enhance yield and reduce costs. Upon passing final testing, REQORSA will be stored at controlled temperatures before distribution. These trials will assess REQORSA in combination with AstraZeneca's Tagrisso® and Merck's Keytruda® in early 2021, potentially impacting the $26.3 billion lung cancer therapeutics market.

Genprex, Inc. (NASDAQ: GNPX) announced the successful completion of the technology transfer for its lead drug candidate, REQORSA™. This achievement signifies the first commercial-scale production in a cGMP-compliant facility, previously conducted at a major cancer research institution. The company expects enhanced production reliability and scalability, crucial for their upcoming Acclaim-1 and Acclaim-2 clinical trials involving combinations of REQORSA with Tagrisso® and Keytruda®. This milestone represents a significant step forward in Genprex’s drug development efforts.

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, will present at the Benzinga Global Small Cap Conference on December 8. CEO Rodney Varner will provide insights on recent advancements in the Acclaim-1 clinical trial. The virtual event aims to connect small-cap companies with investors, offering opportunities for one-on-one engagement. Genprex focuses on developing innovative therapies for cancer and diabetes, particularly through its lead product, REQORSA™, which targets non-small cell lung cancer. Registration for the conference is available online.

Genprex, Inc. (NASDAQ: GNPX) has begun recruitment for its Acclaim-1 clinical trial targeting non-small cell lung cancer (NSCLC). This Phase 1/2 trial will assess the efficacy of REQORSA™ immunogene therapy combined with AstraZeneca's Tagrisso in late-stage NSCLC patients with EGFR mutations. The trial plans to enroll approximately 100 patients across 10 U.S. sites, with an interim analysis after 53 events. Genprex received FDA Fast Track Designation for this trial, enhancing its market potential.

Genprex, Inc. (NASDAQ: GNPX) announced its participation in the Diamond Equity Research Emerging Growth Invitational, set for December 1, 2020, at 11:40 a.m. EST. Executive Vice President Michael Redman will present a company overview and engage in a Q&A session. The virtual event aims to showcase Genprex's advancements in gene therapies for cancer and diabetes. The company's leading drug candidate, REQORSA™, is in development for non-small cell lung cancer and has received Fast Track Designation from the FDA. More details can be found on Genprex's website.

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, announced that Thomas Gallagher, Senior VP of Intellectual Property and Licensing, will join a panel at the virtual Life Sciences Summit on November 17-18, 2020. The panel, titled “Show Me the Money: Preparing Your Company for Funding,” aims to guide emerging companies in securing funding. Key topics will include intellectual property strategy, due diligence, and investor relations. The Life Sciences Summit connects early-stage investors with innovative companies and academic professionals to advance clinical developments.

Genprex, Inc. (NASDAQ: GNPX) has appointed Dr. George K. Gittes to its Scientific Advisory Board. Dr. Gittes is recognized for his work on the company's diabetes gene therapy technology, which has the potential to provide a cure for diabetes, affecting over 30 million people in the U.S. This addition is expected to enhance Genprex’s strategy as it advances its diabetes clinical development program. Rodney Varner, President and CEO of Genprex, noted the importance of Dr. Gittes' expertise in driving the company's efforts to benefit patients with diabetes.

Genprex, Inc. (NASDAQ: GNPX) announced the launch of new branding for its upcoming oncology clinical trials combining its lead drug candidate, REQORSA™ (quaratusugene ozeplasmid), with AstraZeneca’s Tagrisso® (osimertinib) and Merck’s Keytruda® (pembrolizumab) for non-small cell lung cancer (NSCLC). The trials, branded as 'Acclaim,' aim to provide hope for NSCLC patients. Acclaim-1 targets late-stage NSCLC with mutated EGFRs, while Acclaim-2 targets low expressors of PD-L1. The trials are expected to commence in the first half of 2021.